Constantiam Biosciences at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Constantiam Biosciences at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Constantiam Biosciences Cambridge, Massachusetts	1 Co-founder and CSO
constantiambio.com\|LinkedIn Private company Constantiam develops functional genomics platforms for biopharma, diagnostics, and clinical genetics. Its pipeline includes oral small-molecule chaperones for rare lysosomal diseases. Signed a strategic collaboration with Cincinnati Children's, including an exclusive option for future licensing of Gaucher disease therapies. › Signed a strategic collaboration with Cincinnati Children's, including an exclusive option for future licensing of Gaucher disease therapies. 2026-07 · source Agreed with OHSU to license genetic data from Dr. [name]'s lab, expanding its data assets. 2025-09 · source Was awarded a $2.05 million Phase II SBIR grant from NHGRI, federal funding for its research. 2025-09 · source Source: company newsroom $2.05M Phase II SBIR grant from NHGRI (Sep 2025) › A federal research grant, not an equity round; no investor-led financing amount was disclosed. · 2025-09-22 “it has been awarded a $2.05 million Phase II Small Business Innovation Research (SBIR) grant from the US National Human Genome Research Institute (NHGRI).” Source: funding announcement No openings posted	Poster Wed Oct 21 2:30 pm Part of Molecular Effects of Genetic Variation Poster Wednesday Session Massively-multiplexed functional characterization of lysosomal storage disease gene variants Exhibit & Poster Hall · Board 6043W Genetic variationRare variantsLysosomal diseasesGenomics

Organization

ASHG 2026 Attendance

Constantiam Biosciences

Cambridge, Massachusetts

1 Co-founder and CSO

constantiambio.com|LinkedIn

Private company

Constantiam develops functional genomics platforms for biopharma, diagnostics, and clinical genetics. Its pipeline includes oral small-molecule chaperones for rare lysosomal diseases.

Signed a strategic collaboration with Cincinnati Children's, including an exclusive option for future licensing of Gaucher disease therapies.

›

Signed a strategic collaboration with Cincinnati Children's, including an exclusive option for future licensing of Gaucher disease therapies.

2026-07 · source

Agreed with OHSU to license genetic data from Dr. [name]'s lab, expanding its data assets.

2025-09 · source

Was awarded a $2.05 million Phase II SBIR grant from NHGRI, federal funding for its research.

2025-09 · source

Source: company newsroom

$2.05M Phase II SBIR grant from NHGRI (Sep 2025)

›

A federal research grant, not an equity round; no investor-led financing amount was disclosed. · 2025-09-22

“it has been awarded a $2.05 million Phase II Small Business Innovation Research (SBIR) grant from the US National Human Genome Research Institute (NHGRI).”

Source: funding announcement

No openings posted

Poster

Wed Oct 21
2:30 pm

Part of Molecular Effects of Genetic Variation Poster Wednesday Session

Massively-multiplexed functional characterization of lysosomal storage disease gene variants

Exhibit & Poster Hall · Board 6043W

Genetic variationRare variantsLysosomal diseasesGenomics